Complete Revascularization after Pharmacoinvasive Strategy

Patients initially receiving pharmacoinvasive strategy for ST elevation myocardial infarction (STEMI) also presenting multivessel disease consistently benefit from complete revascularization. This benefit is similar to that of primary PCI.  

Revascularización completa luego de estrategia fármaco invasiva

The COMPLETE showed that staged non-culprit lesion percutaneous coronary intervention (PCI) reduced major cardiovascular events in STEMI patients with multivessel coronary artery disease. This benefit was not clear for patients initially receiving antithrombotic medication not being able to access PCI right away. 

Following successful culprit lesion PCI, STEMI 4041 patients with multivessel disease were randomized to either routine non-culprit lesion PCI or culprit lesion only PCI. 

In a COMPLETE prespecified analysis, effect in 303 patients undergoing a pharmacoinvasive strategy was determined against 3738 patients undergoing primary PCI. Two primary end points were defined: on the one hand, cardiovascular death or new myocardial infarction and on the other hand, cardiovascular death, new myocardial infarction, or ischemia-driven revascularization. 

The first primary end point was reduced with complete revascularization both in the patients undergoing a pharmacoinvasive strategy (2.1% vs 4.7%, HR 0.45, 95% CI, 0.21–0.97) and in patients undergoing primary PCI (2.7% vs 3.6%, HR 0.77, 95% CI, 0.62–0.95; interaction P=0.18). 


Read also: SOLACI PERIPHERAL | Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection.


The second primary end point was also reduced significantly with complete revascularization in patients undergoing an initial pharmacoinvasive strategy and in patients undergoing primary PCI.

Conclusion

Patients with multivessel disease with STEMI benefit from complete revascularization after treating the culprit lesion both with primary PCI and initial pharmacoinvasive strategy. 

Orignal Title: Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment–Elevation Myocardial Infarction: Insights From the COMPLETE Trial.

Reference: Payam Dehghani et al. Circ Cardiovasc Interv. 2021 Aug;14(8):e010458. doi: 10.1161/CIRCINTERVENTIONS.120.010458.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Left Main Coronary Artery Disease: Intravascular Imaging-Guided PCI vs. Coronary Artery Bypass Grafting

Multiple randomized clinical trials have demonstrated superior outcomes with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in patients with left main...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...